Skip to content

    Recently Viewed

      Listening...

      Home / Latest news /
      A message from Chairman and CEO Alex Gorsky about Johnson & Johnson’s investigational COVID-19 vaccine candidate
      lede-A Message from Chairman and CEO Alex Gorsky About Johnson & Johnson's Investigational COVID-19 Vaccine Candidate.jpg

      A message from Chairman and CEO Alex Gorsky about Johnson & Johnson’s investigational COVID-19 vaccine candidate

      The company leader shares the latest news about topline results from the Phase 3 clinical trial for its single-dose investigational COVID-19 vaccine candidate.

      Share Article
      share to

      One year ago this week, Johnson & Johnson pledged that we would leverage all of our capabilities to fight an emerging threat, then being referred to as simply “the novel coronavirus.” Since then, we have focused our efforts on delivering a single-dose vaccine that would be a safe, effective and efficient solution for the largest number of people around the world.

      I couldn’t be more proud—or grateful—to share that we have made a significant step towards reaching our ambitious goal.

      Today, we shared positive topline Phase 3 clinical trial results for our single-dose investigational COVID-19 vaccine candidate. We will continue to work with health authorities around the world on regulatory applications.

      Johnson & Johnson was built for times like these—and from day one, we have kept science, transparency and collaboration at the center of all our efforts to fight this deadly pandemic.

      COVID-19 has touched the lives of every person on this planet and tested us as a society and as individuals. But Johnson & Johnson was built for times like these—and from day one, we have kept science, transparency and collaboration at the center of all our efforts to fight this deadly pandemic. Our work on an investigational COVID-19 vaccine will be an enduring point of pride for us for decades to come.

      Doing our part to combat the greatest public health crisis in living memory has been a huge undertaking for our company. I owe a deep debt of gratitude to the incredible teams that made this milestone a reality, and to each and every one of my 135,000 colleagues for living into Our Credo values with great resilience and agility to ensure we keep meeting the healthcare needs of all who rely on Johnson & Johnson.

      COVID-19 continues to inflict heartbreak and hardship, and there is still much that must be done to bring this pandemic to an end. But I am more optimistic than ever that these dark days are numbered.

      I hope that our announcement today serves as a welcome reminder of the transformative power of science, the multiplying effect of collaboration and—most of all—the possibility of a better, healthier future.

      Stay Up to Date on Johnson & Johnson’s Janssen COVID-19 Vaccine

      See answers to frequently asked questions, learn about the company’s innovative vaccine technology platform and more.
      A close-up view of the novel coronavirus

      More from Johnson & Johnson

      Latest news
      healthcare worker in protective medical gear

      Johnson & Johnson named to Fortune’s 2024 America’s Most Innovative Companies list

      The company’s drive to develop novel solutions for the world’s toughest healthcare challenges has earned it a spot on Fortune’s second annual list.
      Innovation
      Headshots of three Johnson and Johnson female scientists

      Meet 3 leaders who are breaking new ground for women in healthcare

      For International Women’s Day, celebrate the achievements of these amazing female scientists and researchers at Johnson & Johnson.
      Innovation
      Close-up of a woman with low vision receiving an eye exam exam with a doctor shining light into her left eye

      What is low vision?

      Low vision isn’t the same as blindness, but navigating daily life with it is still challenging. For Low Vision Awareness Month, learn the facts—plus, the promising treatment innovations that are in the works.
      You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.